Insulet (PODD) Jefferies Global Healthcare Conference summary

Product innovation and market leadership

• Omnipod 5, a tubeless, wearable, automated insulin delivery system, is driving significant market share gains due to its convenience and integration with leading CGMs like Dexcom G6 and soon G7 and Abbott Libre sensors.

• The product is exceeding expectations in the U.S., U.K., and Germany, with a launch in France imminent and further European expansion planned.

• Omnipod 5 is the only patch pump with AID in the U.S., offering a substantial lead over tube-based competitors.

• Integration with new CGM sensors is expected to unlock access to millions of new patients and accelerate growth.

• A cascade of innovation is planned through 2024 and 2025, supporting continued leadership.

Market outlook and growth strategy

• The insulin pump market is growing, with Omnipod products targeting the large, underpenetrated Type 1 and Type 2 diabetes segments.

• Type 1 market is about 40% penetrated with technology, while Type 2 is less than 5%, representing significant growth potential.

• The company aims to increase U.S. market penetration to 70% or higher, closely following CGM adoption rates.

• Focus remains on converting patients from multiple daily injections to Omnipod therapy, especially in the unpenetrated segments.

• International growth is robust, with guidance raised due to strong performance in Europe and upcoming launches in France, Nordics, and Italy.

Financial performance and guidance

• Raised full-year revenue guidance to 18% growth, with operating margin guidance increased by 50 basis points to 13.5%.

• Margin expansion is driven by scale, productivity initiatives, and a new manufacturing site in Malaysia.

• The company targets about 100 basis points of operating margin improvement per year while continuing to invest in innovation.

• Growth is expected to be strong throughout the year, with some lumpiness by quarter but robust annual performance.